This activity is funded by an independent medical education grant from ViiV Healthcare.

This activity is provided by touchIME.

Faculty & Disclosures

Listen on the go

    • View and download resources from this activity to support your learning and share with colleagues. Select a language to continue.

    Downloads
    Download slides
    Download practice aid
    Download slides
    Download slides
    Download slides
    CORRECT!
    Next question
    Faculty & Disclosures
    Dr Tristan Barber

    Royal Free London NHS Foundation Trust,
    London, UK

    Tristan Barber is a consultant physician in HIV medicine at the Ian Charleson Day Centre, Royal Free Hospital and honorary associate professor at the Institute for Global Health, University College London. read more

    Dr Barber is chair of the European AIDS Clinical Society Young Investigators, honorary secretary and chair of the Education and Scientific Subcommittee for the British HIV Association and chair of the Board of Trustees for the peer support charity Positively UK. 

    Dr Barber established a dedicated frailty service for ageing patients with HIV infection in 2019 (The Sage Clinic). He has a research background in HIV-related neurocognitive impairment and antiretroviral clinical trials. Dr Barber is the current editor-in-chief of HIV Research and Clinical Practice.

    Dr Tristan Barber discloses: Advisory board or panel fees from Gilead Sciences, Janssen, MSD and ViiV Healthcare. Consultancy fees from Gilead Sciences, Janssen, MSD and ViiV Healthcare. Grants/research support from Gilead Sciences, Roche and ViiV Healthcare. Speaker’s bureau fees from Gilead Sciences, Janssen, MSD and ViiV Healthcare.
    Dr Christoph Boesecke

    University of Bonn,
    Bonn, Germany

    Christoph Boesecke is an infectious diseases specialist and senior lecturer at the University of Bonn, Germany. read more

    Dr Boesecke completed his medical studies at Charité University in Berlin, Germany. He received his doctorate in medicine from the University of Hamburg, Germany, for his research in acute HIV infection. He held a 2-year postgraduate position studying integrase inhibitors in acute and chronic HIV infection at the National Centre in HIV Epidemiology and Clinical Research (now The Kirby Institute) in Sydney, Australia.

    His main areas of research are comorbidities and coinfections in people living with HIV, including COVID19 and monkeypox.

    Dr Christoph Boesecke discloses: Advisory board or panel fees from AbbVie, Gilead Sciences, Johnson & Johnson, MSD, Pfizer and ViiV Healthcare. Consultant fees from AbbVie, Gilead Sciences, Johnson & Johnson, MSD, Pfizer and ViiV Healthcare. Grants/research support from DZIF, Hector Foundation, NEAT ID. Speaker’s bureau fees from AbbVie, AstraZeneca, Bavarian Nordic, Gilead Sciences, Johnson & Johnson, MSD, Pfizer and ViiV Healthcare.
    Back to Faculty
    touchINFECTIOUS DISEASES touchINFECTIOUS DISEASES
    Now Playing:
    Up Next:
    Take CE/CME Test
    Start activity

    Tutorial

    These icons indicate there is something to be interacted with. Click it when you see it.

    Poll

    What is the key cause of treatment dissatisfaction for people with HIV in your care?

    Submit your answer to see the results

    Side effects
       
    Pill burden
       
    Risk of involuntary disclosure of HIV status
       
    Need for daily administration
       

    Tutorial

    These icons indicate there is something to be interacted with. Click it when you see it.

    Poll

    What do you think is the biggest challenge in optimizing ART for your patients?

    Submit your answer to see the results

    Dealing with stigma or self-stigma
       
    Comorbidities or coinfections
       
    Drug–drug interactions
       
    Socio-economic factors
       

    Tutorial

    These icons indicate there is something to be interacted with. Click it when you see it.

    Poll

    How confident are you  in selecting an appropriate ART regimen for your patients?

    Submit your answer to see the results

    Not confident
       
    A little confident
       
    Moderately confident
       
    Very confident
       
     
    Selecting ART regimen: Available options and how to navigate them
    Shared decision-making: Working with people living with HIV to improve ART outcomes
    Identifying treatment dissatisfaction in people living with HIV: When to revise ART regimen
    Take CE/CME Test

    touchIN CONVERSATION
    A relaxed discussion between two faculty focussed on real world clinical issues. Useful tips below will show how to navigate the activity. Join the conversation. Close

    Selecting ART: Working with people living with HIV to find the best regimen

    Faculty Podcast Featured
    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German, Spanish.
    • A practice aid is available for this activity in the Toolkit
    • Downloads including slides are available for this activity in the Toolkit
    Learning Objectives

    After watching this activity, participants should be better able to:

    • Compare antiretroviral treatment regimens and the implications these differences may have on patients
    • Appraise best practices for shared decision-making when selecting antiretroviral therapies
    • Assess the burden of antiretroviral treatment and the need to change regimen to optimize quality of life
    Overview

    In this activity, two HIV experts answer questions from healthcare professionals on how to navigate antiretroviral therapy (ART) options for people living with HIV. They discuss available ART regimens and criteria for treatment selection, best practices for shared decision-making and how to address treatment dissatisfaction.

    This activity is provided by touchIME.

    Target Audience

    This activity has been designed to meet the educational needs of primary care physicians, HIV specialists, infectious disease specialists, genitourinary medicine specialists, specialist nurse practitioners and virologists involved in the management of HIV.

    Faculty

    Dr Tristan Barber discloses: Advisory board or panel fees from Gilead Sciences, Janssen, MSD and ViiV Healthcare. Consultancy fees from Gilead Sciences, Janssen, MSD and ViiV Healthcare. Grants/research support from Gilead Sciences, Roche and ViiV Healthcare. Speaker’s bureau fees from Gilead Sciences, Janssen, MSD and ViiV Healthcare.

    Dr Christoph Boesecke discloses: Advisory board or panel fees from AbbVie, Gilead Sciences, Johnson & Johnson, MSD, Pfizer and ViiV Healthcare. Consultant fees from AbbVie, Gilead Sciences, Johnson & Johnson, MSD, Pfizer and ViiV Healthcare. Grants/research support from DZIF, Hector Foundation, NEAT ID. Speaker’s bureau fees from AbbVie, AstraZeneca, Bavarian Nordic, Gilead Sciences, Johnson & Johnson, MSD, Pfizer and ViiV Healthcare.

    Touch Medical Contributors

    Adriano Boasso has no financial interests/relationships or affiliations in relation to this activity.

    Date of original release: 15 August 2024. 

    This activity is CE/CME accredited

    To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.

    Claim Credit
    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German, Spanish.
    • A practice aid is available for this activity in the Toolkit
    • Downloads including slides are available for this activity in the Toolkit

    You may also be interested in...

    touchIN CONVERSATION

    Selecting ART: Working with people living with HIV to find the best regimen

    LAUNCH ACTIVITY

    JOURNALS

    Lenacapavir for the Treatment of Heavily Treatment-experienced People with Multi-class Resistant HIV

    GO TO ARTICLE

    JOURNALS

    The Mosaico HIV Vaccine Study: A Step Back or a Stepping Stone for Future Vaccine Development?

    GO TO ARTICLE

    touchMDT

    From PrEP to long-term ART in HIV: Overcoming barriers to adherence throughout the journey

    LAUNCH ACTIVITY
    Ole Schmeltz Søgaard

    CONFERENCE HUB

    Ole Schmeltz Søgaard, CROI 2022: Current Status and Future Potential of Broadly Neutralising anti-HIV-1 Antibodies

    GO TO HUB

    CONFERENCE HUB

    Dr Marta Boffito, World AIDS Day 2021: The importance of early antiretroviral treatment and the barriers to adherence to treatment

    GO TO HUB

    Topics covered in this activity

    HIV / Sexually Transmitted Infections / Viral Infections
    REGISTER NOW FOR FREE ACCESS TO
    • 1000+ topical and insightful peer-reviewed journal articles
    • 100+ hours of bite-sized congress highlights
    • 10 major therapy areas packed with the latest scientific advances
    • 150+ specialties offering learn-on-the-go medical education
    • + Concise email updates and newsletters so you never miss out
    Register For Free Now
    This Activity Is Funded By:

    An independent medical education grant from ViiV Healthcare.
    This activity is provided by touchIME.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

    This content is intended only for healthcare professionals.

    Launch date: 15 August 2024.

    Claim Credit
    touchIN CONVERSATION
    Selecting ART: Working with people living with HIV to find the best regimen

    You may also be interested in...

    CONFERENCE HUB

    HIV vaccine advances: insights from CROI 2024

    GO TO HUB

    touchPANEL DISCUSSION

    Shaping ART around individual needs: Maximizing adherence and quality of life

    LAUNCH ACTIVITY

    JOURNALS

    Dementia and Cognitive Concerns as Risk Factors in People with COVID-19 and HIV

    GO TO ARTICLE

    touchMDT

    From PrEP to long-term ART in HIV: Overcoming barriers to adherence throughout the journey

    LAUNCH ACTIVITY

    CONFERENCE HUB

    Onyema Ogbuagu, CROI 2022: Long-acting Lenacapavir in People with Multidrug Resistant HIV – Week 52 Results

    GO TO HUB
    touchREVIEW

    JOURNALS

    touchREVIEWS in Infectious Diseases

    GO TO ARTICLE
    This Activity Is Funded By:

    An independent medical education grant from ViiV Healthcare.
    This activity is provided by touchIME.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

    This content is intended only for healthcare professionals.

    Launch date: 15 August 2024.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup